Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 349

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

Open access
Izquierdo-Sanchez, Laura, Lamarca, Angela, La Casta, Adelaida, Buettner, Stefan, Utpatel, Kirsten, Klümpen, Heinz-Josef, Adeva, Jorge, Vogel, Arndt, Lleo, Ana, Fabris, Luca, Ponz-Sarvise, Mariano, Brustia, Raffaele, Cardinale, Vincenzo, Braconi, Chiara, Vidili, Gianpaolo, Jamieson, Nigel B., Macias, Rocio IR., Jonas, Jan Philipp, Marzioni, Marco, Hołówko, Wacław, Folseraas, Trine, Kupčinskas, Juozas, Sparchez, Zeno, Krawczyk, Marcin, Krupa, Łukasz, Scripcariu, Viorel, Grazi, Gian Luca, Landa-Magdalena, Ana, Ijzermans, Jan NM., Evert, Katja, Erdmann, Joris I., López-López, Flora, Saborowski, Anna, Scheiter, Alexander, Santos-Laso, Alvaro, Carpino, Guido, Andersen, Jesper B., Marin, Jose JG., Alvaro, Domenico, Bujanda, Luis, Forner, Alejandro, Valle, Juan W., Koerkamp, Bas Groot, Banales, Jesus M.·2022·Journal of Hepatology

Abstract

BACKGROUND & AIMS: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incidence and related mortality is increasing. This study investigates the clinical course of CCA and subtypes (intrahepatic [iCCA], perihilar [pCCA], and distal [dCCA]) in a pan-European cohort. METHODS: The ENSCCA Registry is a multicenter observational study. Patients were included if they had a histologically proven diagnosis of CCA between 2010-2019. Demographic, histomorphological, biochemical, and clinical studies were performed. RESULTS: Overall, 2,234 patients were enrolled (male/female=1.29). iCCA (n = 1,243) was associated with overweight/obesity and chronic liver diseases involving cirrhosis and/or viral hepatitis; pCCA (n = 592) with primary sclerosing cholangitis; and dCCA (n = 399) with choledocholithiasis. At diagnosis, 42.2% of patients had local disease, 29.4% locally advanced disease (LAD), and 28.4% metastatic disease (MD). Serum CEA and CA19-9 showed low diagnostic sensitivity, but their concomitant elevation was associated with increased risk of presenting with LAD (odds ratio 2.16; 95% CI 1.43-3.27) or MD (odds ratio 5.88; 95% CI 3.69-9.25). Patients undergoing resection (50.3%) had the best outcomes, particularly with negative-resection margin (R0) (median overall survival [mOS] = 45.1 months); however, margin involvement (R1) (hazard ratio 1.92; 95% CI 1.53-2.41; mOS = 24.7 months) and lymph node invasion (hazard ratio 2.13; 95% CI 1.55-2.94; mOS = 23.3 months) compromised prognosis. Among patients with unresectable disease (49.6%), the mOS was 10.6 months for those receiving active palliative therapies, mostly chemotherapy (26.2%), and 4.0 months for those receiving best supportive care (20.6%). iCCAs were associated with worse outcomes than p/dCCAs. ECOG performance status, MD and CA19-9 were independent prognostic factors. CONCLUSION: CCA is frequently diagnosed at an advanced stage, a proportion of patients fail to receive cancer-specific therapies, and prognosis remains dismal. Identification of preventable risk factors and implementation of surveillance in high-risk populations are required to decrease cancer-related mortality. LAY SUMMARY: Edition (ICD-11) (i.e., intrahepatic [2C12], perihilar [2C18], or distal [2C15] affected bile ducts), which come into effect in 2022. General and tumor-type specific features at diagnosis, risk factors, biomarker accuracy, as well as patient management and outcomes, are presented and compared, outlining the current clinical state of cholangiocarcinoma in Europe.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.12.010

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 349

Metadata

Authors
Izquierdo-Sanchez, L., Lamarca, A., La Casta, A., Buettner, S., Utpatel, K., Klümpen, H.-J., Adeva, J., Vogel, A., Lleo, A., Fabris, L., Ponz-Sarvise, M., Brustia, R., Cardinale, V., Braconi, C., Vidili, G., Jamieson, N. B., Macias, R. I., Jonas, J. P., Marzioni, M., Hołówko, W., Folseraas, T., Kupčinskas, J., Sparchez, Z., Krawczyk, M., Krupa, Ł., Scripcariu, V., Grazi, G. L., Landa-Magdalena, A., Ijzermans, J. N., Evert, K., Erdmann, J. I., López-López, F., Saborowski, A., Scheiter, A., Santos-Laso, A., Carpino, G., Andersen, J. B., Marin, J. J., Alvaro, D., Bujanda, L., Forner, A., Valle, J. W., Koerkamp, B. G., & Banales, J. M.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2022-05
Volume
76
Issue
5
Pages
1109-1121
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4210953361
Cited by
349
References
27
FWCI
62.95
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. https://app.cochat.ai/papers/10.1016/j.jhep.2021.12.010
The paper
Izquierdo-Sanchez, L., Lamarca, A., La Casta, A., Buettner, S., Utpatel, K., Klümpen, H.-J., Adeva, J., Vogel, A., Lleo, A., Fabris, L., Ponz-Sarvise, M., Brustia, R., Cardinale, V., Braconi, C., Vidili, G., Jamieson, N. B., Macias, R. I., Jonas, J. P., Marzioni, M., . . . Banales, J. M. (2022). Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.12.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.